| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-07-01 | Imaxio (France) Jenner Institute (UK) | € 5.5 million | grant | European Commission’s Seventh Framework Program (FP7) European Vaccine Initiative (EU) Preclin Biosystems (Switzerland) | Infectious diseases | Grant |
| 2013-06-27 | Heptares Therapeutics (UK) | $21 million (€16.1 million) | series B financing round | Stanley Family Foundation (SFF) (USA) Clarus Ventures (USA) Takeda Ventures (USA) | Mental diseases - Neurological diseases - Psychiatric diseases | Series B financing round |
| 2013-06-27 | BioVersys (Switzerland) | undisclosed | series A financing round | Infectious diseases | Series A financing round | |
| 2013-06-26 | Diamyd Medical (Sweden) | MSEK 20.7 (€2.32 million) | new shares issue | Metabolic diseases | Private placement | |
| 2013-06-26 | Complix (Belgium) | € 12 million | Series B financing round | Gimv (Belgium) Edmond de Rothschild Investment Partners (France) | Cancer - Oncology - Autoimmune diseases | Series B financing round |
| 2013-06-26 | Forendo Pharma (Finland) | € 1.2 million | first financing round | Karolinska Development (Sweden) Novo Seeds (Denmark) Finnvera (Finland) | Gynecology - Women's health - Hormonal diseases - Endocrine diseases | Series A financing round |
| 2013-06-26 | Kiadis Pharma (The Netherlands) | up to €3 million | credit line | Agentschap NL (The Netherlands) | Cancer - Oncology | Credit line |
| 2013-06-26 | Biotest (Germany) | € 76 million | private placement | Private placement | ||
| 2013-06-25 | CellCentric (UK) | £4.3 million (€ 5 million) | grant | Biomedical Catalyst Fund (UK) Morningside Venture Investments (Hong Kong) Providence Investment Company (UK) Rainbow Seed Fund (UK) | Cancer - Oncology | Grant |
| 2013-06-25 | MDxHealth (Belgium) | €18 Million | private placement of new shares | Valiance Asset Management (UK) Biovest Comm | Diagnostic - Cancer - Oncology | Private placement |
| 2013-06-25 | F2G (UK) | € 6.1 million | grant | European Commission’s Seventh Framework Program (FP7) | Infectious diseases | Grant |
| 2013-06-24 | vasopharm (Germany) | €5 million | series F financing round | HeidelbergCapital Private Equity and Entrepreneurs Fund (EF Investments S.à.r.l.) (Germany) Bayern Kapital (Germany) Hanseatic Asset Management LBG (Guernsey) Dr Andrew Clark, Chairman of the Board of vasopharm | CNS diseases | Fundraising |
| 2013-06-17 | Athera Biotechnologies (Sweden) | € 6 million | grant | European Commission’s Seventh Framework Program (FP7) | Cardiovascular diseases | Grant |
| 2013-06-17 | XO1 (UK) | $11 million (€8.25 million) | series A financing round | Index Ventures (Switzerland) | Cardiovascular diseases - Hematological diseases | Series A financing round |
| 2013-06-13 | apceth (Germany) | € 22 million | financing round | existing investors | Fundraising | |
| 2013-06-07 | Diagnoplex (Switzerland) | 1.3 million Swiss francs (€1.03 million) | financing round | Debiopharm (Switzerland) Neomed (Switzerland) Initiative Capital Romandie (Switzerland) |
Diagnostic - Cancer - Oncology | Financing round |
| 2013-06-04 | BrainStorm Cell Therapeutics (USA - Israel) | 1.2 Million NIS (€ 0.25 million) | grant | Office of the Chief Scientist (OCS -Israel) | Neurodegenerative diseases | Grant |
| 2013-06-04 | Autifony Therapeutics (UK) | £5.5 million (€ 6.4 million) | series A financing round | Pfizer Venture Investments (USA) | Otorhinolaryngology | Series A financing round |
| 2013-05-30 | Oramed Pharmaceutical (Israel) | NIS 975,000 (approximately US$265,000 or € 203,000) | grant | Metabolic diseases | Grant | |
| 2013-05-30 | Targovax (Norway) | NOK 20 million (€2.65 million) | grant, financing round | The Radium Hospital Research Foundation (Norway) Algot Ivest, Trygve Schiørbeck, new and existing owners | Cancer - Oncology | Grant |
